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a  b  s  t  r a  c t
A  restrictive antibiotic policy  banning  routine use of ceftriaxone and  ciprofloxacin  was implemented
in  a 450-bed  district  general  hospital  following  an  educational campaign. Monthly  consumption  of
nine  antibiotics  was monitored  in defined daily  doses  (DDDs)  per 1000  patient-occupied  bed-days
(1000  pt-bds)  9 months  before  until 16 months after  policy  introduction. Hospital-acquired Clostridium
difficile,  meticillin-resistant  Staphylococcus  aureus  (MRSA)  and  extended-spectrum  -lactamase  (ESBL)-
producing  coliform  cases  per  month/1000  pt-bds were  identified  and reviewed throughout  the  hospital.
Between  the  first and final  6 months  of the  study,  average monthly  consumption  of ceftriaxone  reduced
by  95%  (from 46.213 to 2.129 DDDs/1000  pt-bds)  and  that  for ciprofloxacin  by  72.5% (109.804 to 30.205
DDDs/1000  pt-bds). Over the  same periods,  hospital-acquisition  rates  for  C. difficile  reduced  by  77% (2.398
to  0.549  cases/1000  pt-bds), for  MRSA  by  25%  (1.187 to  0.894  cases/1000 pt-bds)  and  for  ESBL-producing
coliforms  by  17% (1.480  to  1.224  cases/1000  pt-bds). Time-lag  modelling confirmed significant associ-
ations between ceftriaxone  and  C.  difficile  cases  at  1  month (correlation  0.83;  P <  0.005),  and between
ciprofloxacin  and ESBL-producing  coliform  cases  at  2 months  (correlation  0.649;  P =  0.002).  An  audit
performed  3 years  after  the  policy showed  sustained  reduction  in C. difficile rates (0.259 cases/1000
pt-bds),  with additional decreases  for  MRSA  (0.409 cases/1000 pt-bds)  and  ESBL-producing  coliforms
(0.809 cases/1000 pt-bds). In  conclusion,  banning  two  antibiotics  resulted  in an  immediate  and  profound
reduction  in hospital-acquired C. difficile,  with  possible longer-term  effects  on MRSA  and  ESBL-producing
coliform  rates.  Antibiotic  stewardship is fundamental  in the  control  of major hospital  pathogens.
© 2012 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
1. Introduction
There are continuing concerns over hospital-acquired infections
(HAIs) caused by  Clostridium difficile, meticillin-resistant Staphy-
lococcus aureus (MRSA) and extended-spectrum -lactamase
(ESBL)-producing coliforms [1].  It  is already known that these
pathogens are associated with antibiotic consumption, with some
classes encouraging certain organisms more than others [1–3].
Intensive use of cephalosporins or quinolones, for example, has
been linked with increasing rates of C. difficile,  MRSA and/or ESBL-
producing coliforms, whilst reduced consumption has facilitated
∗ Corresponding author. Tel.: +44 1355 585 000; fax: +44 1355 584 350.
E-mail address: stephanie.dancer@lanarkshire.scot.nhs.uk (S.J. Dancer).
decreased rates of one or more of these pathogens [1–5].  As a
response to high rates of HAIs, it was  decided to impose a  restric-
tive antibiotic policy banning the routine use of third-generation
cephalosporins, specifically ceftriaxone, and quinolones through-
out the hospital. Prospective surveillance programmes were set
up to monitor rates of hospital-acquired C. difficile, MRSA and
ESBL-producing coliforms. Previous studies have not necessarily
monitored the effect of such a  policy for a  whole hospital, nor have
they included surveillance of all three pathogens simultaneously.
The aim of stewardship was primarily to  reduce the number of
C. difficile cases, although it was hoped that the policy would
also impact on MRSA and ESBL-producing coliforms. This arti-
cle describes how prescribing practices were changed and what
happened after two  key antibiotics were removed from first-line
prescribing on a  hospital-wide basis.
0924-8579/$ – see front matter ©  2012 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
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2. Materials and methods
2.1. Antimicrobial policy implementation
Hairmyres Hospital is a  450-bed district general hospital in  a
rural area just outside Glasgow, UK. The hospital admits adult
patients only, specialising in  care of the elderly, respiratory,
endocrinology and cardiology, with most surgical specialties rep-
resented, including orthopaedics, vascular, ear, nose and throat
(ENT), and ophthalmology. There is  an Accident & Emergency
(A&E) department, a  high dependency unit and an 8-bed Intensive
Care Unit (ICU). Antimicrobial prescribing policies for empir-
ical treatment of various infections and surgical prophylaxis
are overseen by a Healthboard Infection Committee; day-to-day
advice on antimicrobial prescribing is provided by  one consultant
microbiologist, who also authorises microbiological results. The
microbiologist is supported by an on-site Clinical Pathology Accred-
itation (CPA)-accredited laboratory, out-of-hours cross cover by
colleagues at neighbouring hospitals and two infection control
nurses.
Specific concern over C. difficile was raised following increasing
cases among hospital in-patients during January 2008. Surveillance
figures published later that year confirmed the high rate of C. dif-
ficile compared with other Scottish hospitals [6]. It was decided
to initiate an educational programme encouraging prescribers to
reduce consumption of cephalosporins and quinolones on a vol-
untary basis. This was done by  providing a  series of lectures to  all
medical staff starting in  January 2008 as well as weekly teaching
for small groups of junior doctors. A letter summarising the prob-
lem and requirement for prescribing change was sent to all senior
staff, including doctors, pharmacists and managers. Daily micro-
biological authorisation suppressed release of cephalosporins and
quinolones on ward reports unless no other agents were avail-
able. Ad hoc discussion took place when ward doctors phoned for
advice on individual patients, with restricted agents either stopped
or changed to alternative therapy.
From January 2008, the infection control team initiated prospec-
tive  surveillance of all cases of C.  difficile, MRSA and ESBL-producing
coliforms on a ward-by-ward basis using national guidelines and
definitions. Monthly consumption of antibiotics was collected and
recorded in defined daily doses (DDDs) per 1000 patient-occupied
bed-days (pt-bds) (http://www.whocc.no/atc ddd index/).
Macrolides (erythromycin and clarithromycin), ceftriaxone,
amoxicillin, amoxicillin/clavulanic acid, piperacillin/tazobactam,
gentamicin, ciprofloxacin and meropenem were monitored. Infor-
mation Management provided monthly bed occupancy figures for
the hospital using the hospital TrakCare® system.
Following a small outbreak of C. difficile on the gastroen-
terology ward in May  2008, formal restriction of cephalosporins
and quinolones was proposed. This began during August 2008,
to coincide with hospital-wide changeover of junior doctors.
The antimicrobial policy was contained within an induction pro-
gramme  for all new doctors. Empirical prescription of ceftriaxone
for systemic sepsis and surgical prophylaxis was changed to
amoxicillin, gentamicin and metronidazole. The most notable inter-
vention was complete removal of ceftriaxone and ciprofloxacin
from all wards except for A&E and the ICU. The educational pro-
gramme  then continued for prescribers on a  regular basis, with
feedback on HAI rates sent to  clinicians and managers from late
2008. The antibiotic policy continued after the study finished in
December 2009.
Preliminary data from this study were presented at the 20th
European Congress of Clinical Microbiology and Infectious Dis-
eases (ECCMID), 10–13 April 2010, Vienna, Austria. One year later,
2011 rates of C. difficile,  MRSA and ESBL-producing coliforms were
audited using the same definitions in order to gauge long-term
effects of the restrictive policy. HAI and bed occupancy data were
subsequently collected on a monthly basis throughout 2011.
2.2. Surveillance definitions
Specimens were sent to the laboratory when clinically indicated.
Hospital-acquired C.  difficile was defined as onset of symptoms
>48 h after admission (or with onset of symptoms in  the commu-
nity following hospital admission within the previous 4 weeks)
along with a  positive C. difficile toxin test. Hospital-acquired MRSA
was confirmed if  MRSA was  isolated from any specimen >48 h
after hospital admission, with no previous record of MRSA carriage
or infection. Similarly, ESBL-producing coliform isolated from any
specimen >48 h after admission was  defined as hospital-acquired,
with no previous record of ESBL-producing coliform carriage or
infection. Whilst screening for these organisms was  not routinely
performed during 2007–2009, patients awaiting elective surgery
were offered MRSA screening (nose, perineum and wounds) and
urinalysis.
Determination of new acquisitions was performed system-
atically for all patients following laboratory confirmation. After
excluding duplicate specimens, each new acquisition alert was sub-
jected to rigorous investigation, including inspection of patient
notes, details on previous hospital admission(s), antimicrobial ther-
apy and review of microbiological history using the laboratory
database. Whilst new acquisitions of C. difficile were generally con-
clusive, investigation of potential new acquisitions of MRSA and
ESBL-producing coliforms often revealed prior acquisition months
or  even years before the current admission and these patients
were excluded. There were no genotyping data to confirm persis-
tent carriage of specific strains, but  the database held details of
previously isolated organisms with full antibiogram. This helped
evaluate long-term carriage of specific phenotypes of MRSA and
ESBL-producing coliforms. Microbiological results for individual
patients moving between hospital and the community could be
tracked for a  decade or more.
Patients lacking historical microbiological data and/or history
of recent (within 1 year) hospital admission and/or transfers from
another hospital or healthcare institution were excluded, as well
as frequent hospital attendees due to chronic disease. Patient
notes were tagged for future reference following confirmation
of acquisition. Enhanced investigation of all potential acquisi-
tions was  maintained throughout the study owing to the fact that
patients were not routinely screened for study organisms. Universal
screening for MRSA was  introduced as national policy in 2010.
Healthboard policies were  applied throughout the whole hos-
pital by the same infection control team. Other than sporadic
ward closures due to norovirus, there were no outbreaks caused
by any of the three organisms under surveillance, apart from
the cluster of C. difficile cases previously mentioned, and there
were no additional infection control interventions over the study
period.
2.3. Laboratory methods
Isolation and identification of C. difficile, MRSA and ESBL-
producing coliforms from patient specimens were subject to
standard operating procedures in an accredited NHS microbiol-
ogy laboratory. Briefly, C.  difficile in liquid stool was confirmed by
enzyme immunoassay assay (C. difficile Tox A/B II; TechLab Inc.),
with a  proportion of cultured isolates sent to a  reference facility for
further characterisation. Selection of isolates for typing adhered to
reference laboratory recommendations, e.g. investigation of case
clusters, fatal outcome and multiple occurrences.
Specimens from all sites were cultured on Oxoid Brilliance Chro-
mogenic MRSA agar overnight and suspect colonies were checked
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Table 1
Monthly rates of hospital-acquired meticillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile and extended-spectrum -lactamase (ESBL)-producing coliforms
and  consumption of key antibiotics following introduction of a restrictive antibiotic policy for 2  years.
Date Rate (/1000 pt-bds) Consumption (DDDs/1000 pt-bds)
MRSA C. difficile ESBL-producing coliforms CFX  GEN TZP AMX  AMC Macro CIP MER
Nov. 2007 n/c n/c 1.220 58.713 19.068 12.210 144.579 274.5  35.64 51.68 13.834
Dec.  2007 n/c 1.883 1.130 83.254 24.800 21.705 223.582 363.147 39.27 96.571 8.005
Jan. 2008 2.078 3.03 1.212 70.515 27.991  12.690 131.861 272.06 43.74 87.654 4.545
Feb. 2008 0.735 1.837 1.377 44.219 21.122  11.601 160.139 336.909 30.83 96.905 8.265
Mar. 2008 1.081 2.972 1.171 54.535 26.867  14.533 138.363 265.243 36.90 52.526 7.881
Apr. 2008 1.130 1.977 1.695 41.612 44.879  15.191 141.310 146.921 33.48 142.045 12.945
May  2008 1.433 2.580 1.147 34.595 40.300 25.281 134.27 247.343 37.20 128.937 8.123
June 2008 0.664 1.993 2.278 31.800 34.333  18.428 122.662 264.233 35.64 150.755 9.255
July 2008 0.751 0.751 1.408 27.509 41.780 19.405 162.473 215.995 32.13 146.747 7.746
Aug. 2008 0.497 0.795 1.889 5.668 20.384 18.505 167.023 177.468 29.26 118.345 4.474
Sept. 2008 0.932 1.553 2.795 4.347 39.675  12.21 257.711 180.944 43.50 82.124 3.364
Oct. 2008 0.870 0.580 1.644 1.692 39.476  12.99 259.62 153.476 44.93 57.411 2.66
Nov. 2008 1.403 1.309 0.842 2.619 60.799 10.773 260.499 172.145 42.46 73.931 4.911
Dec. 2008 1.082 0.541 1.442 2.884 88.33 16.139 505.858 266.805 70.03 68.265 5.858
Jan. 2009 0.802 0.356 0.713 1.912 80.23 12.55 271.684 140.649 47.13 105.17 4.903
Feb. 2009 0.728 0.312 1.04 2.496 64.832  14.376 312.981 182.016 42.59 64.76 3.640
Mar. 2009 0.738 0.277 1.845 1.015 63.653  18.295 254.336 157.300  40.27 50.387 4.612
Apr. 2009 1.375 0.458 0.825 2.933 56.365  18.412 193.52 118.733 43.4 10.503 5.957
May  2009 0.534 0.802 0.98 2.316 70.372 19.126 284.874 117.967 44.81 27.632 6.235
June 2009 1.359 0.291 0.874 1.310 82.343  18.533 248.932 159.02 41.62 30.072 2.184
July 2009 0.559 0.559 1.676 4.376 80.382 25.012 364.97 141.676 29.19 28.305 7.682
Aug. 2009 0.933 1.027 1.587 1.166 71.236  18.029 216.239 165.273 30.19 36.211 9.800
Sept. 2009 0.865 0.288 0.865 0.576 72.220 14.920 281.013 135.62  36.27 27.308 6.966
Oct. 2009 0.765 0.510 1.020 3.188 76.670 14.922 345.761 102.57 37.81 26.87 2.551
Nov. 2009 0.882 0.617 1.323 2.161 93.066 20.67 324.32 125.803 45.85 32.463 2.426
pt-bds, patient-occupied bed-days; DDDs, defined daily doses; CFX, ceftriaxone; GEN, gentamicin; TZP, piperacillin/tazobactam; AMX, amoxicillin; AMC, amoxicillin/clavulanic
acid; Macro, macrolides (erythromycin and clarithromycin); CIP, ciprofloxacin; MER, meropenem; n/c, not collected.
The educational component of restrictive antibiotic policy began in December 2007; formal component of policy was introduced in July 2008.
for coagulase production using Staph Xtra Latex (Pro-Lab Diagnos-
tics) followed by tube coagulase. Presumed MRSA were tested for
penicillin-binding protein using Latex PBP2I (Oxoid Ltd.) and VITEK
2 analyses for confirmation and antibiogram. Sporadic isolates were
sent to a reference facility according to  national protocol.
ESBL-producing coliforms were also identified using the VITEK
2 analyser, accompanied by standard cephalosporin and clavulanic
acid disk testing (Mast Diagnostics). The definition of ‘coliforms’
used was lactose-fermenting Gram-negative non-spore-forming
bacilli capable of producing acid and gas when incubated at
35–37 ◦C. The following genera and species were identified and
included: Escherichia coli;  Klebsiella spp. (mostly Klebsiella pneumo-
niae); Enterobacter spp. (mostly Enterobacter cloacae); Serratia spp.
(mostly Serratia marcescens);  Hafnia alvei; and Citrobacter koseri.
Over 95% of the ESBL-producing Gram-negative bacilli identified
were E. coli and K.  pneumoniae. Any unidentifiable isolates and/or
those showing resistance to  carbapenem agents were sent to a ref-
erence laboratory for verification.
2.4. Statistics
A Poisson regression model (adjusted for overdispersion) was
used with log occupied bed-days as an offset. Linear trend terms
were used to assess temporal changes. The main hypothesis was to
see whether the trend in  HAI rates following antimicrobial restric-
tion was the same as the trend before the intervention. If that
hypothesis was not rejected, then there was a  further test of the
effect of the restrictions in shifting the level of HAI cases. Variable
selection was based upon Akaike information criterion (AIC), and
residual analysis was used to assess model fit and serial correlation.
Correlations between cases of ESBL-producing coliforms and
ciprofloxacin or ceftriaxone (adjusted for patient-occupied bed-
days) were calculated at time lags  of 0–5 months. Poisson
regression was again used to  assess which of the antibiotics was
the better predictor of ESBL-producing coliform cases.
3.  Results
Average monthly consumption of ceftriaxone reduced from
46.213 DDDs/1000 pt-bds for January–June 2008 to  2.129
DDDs/1000 pt-bds for June–November 2009 (95% reduction).
Over the same periods, ciprofloxacin consumption decreased
from 109.804 to 30.205 DDDs/1000 pt-bds (72.5% reduction). The
pre-intervention hospital-acquisition MRSA rate during the ini-
tial 6 months was 1.187 cases/1000 pt-bds, decreasing to 0.894
cases/1000 pt-bds (25% reduction) for the final 6 months of  the
study; for C.  difficile it was  2.398 cases/1000 pt-bds, decreasing to
0.549 cases/1000 pt-bds (77% reduction); and for ESBL-producing
coliforms it was  1.480 cases/1000 pt-bds, decreasing to 1.224
cases/1000 pt-bds (17% reduction).
Prior to formal introduction of the policy in  August 2008, the
rate of C. difficile cases was  already decreasing at  a rate of  6.59%
per month [95% confidence interval (CI), –2.52%, 15.02%; P =  0.169]
(Table 1; Fig. 1). This was attributed to the educational component
of the intervention, which could explain the lack of policy effect
on the changing trend of C. difficile infections (P =  0.69). Adjusting
for the decreasing trend, the policy was associated with a  45.22%
reduction (95% CI, –4.79%, 72.05%; P =  0.09) in the rate of C.  difficile
infections. If the trend is  ignored, which is reasonable for the data
from December 2007 to June 2008, then the policy was associated
with a  70.20% (95% CI, 57.12%, 79.53%) reduction in  the rate of C.
difficile.
For MRSA, there was no evidence of any effect of the restrictive
policy on the trend (P =  0.78) nor on the rates of MRSA acquisi-
tion following introduction of the policy (P =  0.62). The total MRSA
acquisition rate was constant over the study period. The MRSA bac-
teraemia rate in this hospital was  initially low (0.4 cases/1000 acute
occupied bed-days) and did not change during the study. For ESBL-
producing coliforms, there was borderline evidence of an effect of
the policy on the trend (P =  0.075), which gave an 8.21% (95% CI,
−0.39%, 16.15%) reduction.
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Fig. 1. Hospital-acquired meticillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile and extended-spectrum -lactamase (ESBL)-producing coliform rates fol-
lowing a  restrictive antibiotic policy in a district general hospital over  2  years. pt/occ.bds, patient-occupied bed-days; DDDs, defined daily doses.
Based upon AIC, backward selection within the Poisson regres-
sion model using an overdispersed distribution showed that the
antibiotics most associated with the temporal changes of C.  dif-
ficile were ceftriaxone (rates decrease as ceftriaxone consumption
decreases) and amoxicillin (rates decrease as amoxicillin consump-
tion increases) (Table 2). Time-lag modelling showed a 1-month
association between ceftriaxone and C.  difficile cases (correlation
0.83; P < 0.005).
Time-lagged investigation (0–5 months) was used to  exam-
ine possible associations between ciprofloxacin consumption and
ESBL-producing coliform infections (correlation 0.36: P  = 0.08)
(Table 2; Fig. 2). Adjusting for any association between ceftriaxone
and ESBL-producing coliform rates, ciprofloxacin consumption
and ESBL-producing coliform rates were associated at lags 0, 1
and 2 months (Fig. 3). The strongest association occurred at a
lag  of 2 months (correlation 0.649; P =  0.002), whilst associations
at lags 0 and 1 month are borderline (P  =  0.047 and P =  0.044,
respectively). ESBL-producing coliform rates increased as monthly
ciprofloxacin consumption increased for all three lags. Adjusting
for the association between ciprofloxacin and ESBL-producing col-
iform rates, there was no association between ESBL-producing
coliforms and ceftriaxone consumption at any lag between 0 and
5 months.
This study finished at the end of 2009, but restrictions on
ciprofloxacin and ceftriaxone have continued. Low rates of C.
difficile have been maintained, as during 2011 monthly rates
varied between 0.2 and 0.6 cases/1000 pt-bds, with an aver-
age rate of 0.259 cases/1000 pt-bds (data not shown). We
also found decreased numbers of patients acquiring MRSA and
ESBL-producing coliforms. In 2011, the average monthly hospital-
acquired rate for ESBL-producing coliforms was 0.809 cases/1000
pt-bds and for MRSA it was 0.409 cases/1000 pt-bds, with
an MRSA bacteraemia rate of 0.2 cases/1000 acute occupied
bed-days. These rates represent further reductions for all three
pathogens.
4. Discussion
Introducing and reinforcing a  restrictive antimicrobial policy
in  this hospital had a  rapid and profound effect on the rate of
hospital-acquired C.  difficile.  The relationship between consump-
tion of broad-spectrum antibiotics and C. difficile rates has already
been established, with the highest risk for C. difficile infection within
the first month following antibiotic use [1–3,7].  Whilst the most
significant association occurred between C. difficile rate and cef-
triaxone consumption, it is  possible that reduction of cases could
be attributed to  other antibiotic trends. Clostridium difficile iso-
lates were typed and whilst ribotype 0127 was not identified, we
were aware of others that  were uniformly resistant to  quinolone
antibiotics. Targeting both ceftriaxone and ciprofloxacin may  have
ultimately been the most important factor in  decreasing C. difficile
rates.
At the time of this study, there were no national data on antimi-
crobial consumption for individual hospitals. This was  one of  the
reasons that we decided to examine our  infection rates against con-
sumption of key antibiotics. Furthermore, there were no national
Table 2
Correlation between antibiotic consumption and acquisition rate of target pathogens per  1000 patient-occupied bed-days over 2 years in a  district general hospital.
Antibiotic or antibiotic class Clostridium difficile MRSA ESBL-producing coliforms
Correlation P-value Correlation P-value Correlation P-value
Ceftriaxone 0.83 <0.005 0.13 0.58 −0.02  0.92
Gentamicin −0.70  <0.005 0.07 0.77 −0.30  0.14
Piperacillin/tazobactam −0.06  0.77 −0.05  0.81 0.04 0.84
Amoxicillin −0.65 <0.005 −0.13 0.56 −0.12 0.58
Amoxicillin/clavulanic acid 0.65 <0.005 0.06 0.78 0.11 0.61
Macrolides −0.21 0.34 0.27 0.22 −0.17 0.43
Ciprofloxacin 0.48 0.02 −0.06  0.78 0.36 0.08
Meropenem 0.46 0.03 0.04 0.86 0.09 0.68
MRSA, meticillin-resistant Staphylococcus aureus;  ESBL, extended-spectrum -lactamase.
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Fig. 2. Ciprofloxacin consumption and number of cases of hospital-acquired extended-spectrum -lactamase (ESBL)-producing coliforms. DDDs, defined daily doses;
pt/occ.bds, patient-occupied bed-days.
data on ESBL-producing coliform rates, although we knew that the
MRSA bacteraemia rate was comparable with other Scottish hospi-
tals of similar size.
Spatiotemporal modelling suggests that  reducing patient sus-
ceptibility to C.  difficile infection is more effective for control than
trying to stop transmission once a  patient is infected [8].  This is  sup-
ported by our experience and contrasts with the finding that there
was little or no effect on initial rates of MRSA or  ESBL-producing
coliforms [9]. Infection control procedures for C. difficile may  be
more effective for preventing C.  difficile transmission than those
implemented for patients with either MRSA or ESBL-producing
coliforms. Patients with diarrhoea were prioritised for isolation,
whereas those colonised with MRSA or ESBL-producing coliforms
were not. Whilst some ESBL-producing coliform strains can be
maintained in humans without any identifiable selective pressure,
Fig. 3. Time-lag modelling of ciprofloxacin consumption against extended-
spectrum -lactamase (ESBL)-producing coliform acquisition rates. Adjusting for
any association between ceftriaxone and ESBL-producing coliform rates, there is an
association between ciprofloxacin usage and ESBL-producing coliforms at  lags 0, 1
and 2 months. The strongest association is at a  lag of 2 months (P =  0.002); associa-
tions at lags 0 and 1  month are borderline (P =  0.047 and P =  0.044, respectively).
we found a time–lag relationship between ciprofloxacin consump-
tion and the incidence of ESBL-producing coliforms [1].  It  is possible
that ciprofloxacin use is driving rates of ESBL-producing coliforms
on a hospital-wide basis. This is supported by two studies showing
that fluoroquinolone use correlates with increased ESBL-producing
coliforms in ICU patients, and another linking quinolone use with
ESBL-producing coliforms in hospital and the community. The lat-
ter found a  1-month lag effect between quinolone consumption and
ESBL-producing coliform rates rather than the 2 months reported
here [10–12].
Gaining support for restricting antibiotics among prescribing
colleagues in the hospital initially proved difficult. The educa-
tional component was almost exclusively provided by the on-site
microbiologist and helped reinforce knowledge on  prescribing
practices and the longer-term consequences of antibiotic consump-
tion [2,13].  The effect of the initial education programme is  clearly
seen in Fig. 1, whereby consumption of ceftriaxone decreased even
before the restrictive policy was formally implemented. Advice on
prescribing often conflicted with published guidelines on the man-
agement of a  specific condition, however, which recommended
one or both of the targeted antibiotics. Thus, gastroenterologists
initially refused to curtail ciprofloxacin prescribing for sponta-
neous bacterial peritonitis (SBP) [14].  Restrictions were eventually
accepted after the outbreak in  May 2008, following which inde-
pendent audit was  performed on the microbiological aetiology
of SBP in  order to  improve prescribing practices. By far the best
method of restricting use of a  particular drug was  physical removal
from ward stores by the pharmacists [15].  This meant that doctors
did not  have easy access to banned agents out-of-hours, although
pharmacy would supply it on an individual named-patient basis
following clinical discussion. Routine surveillance confirmed that
unrestricted antibiotic prescribing did not  encourage ICU-acquired
infection caused by MRSA, ESBL-producing coliforms or C. difficile,
but it is  possible that daily ward rounds by the on-site microbiolo-
gist helped control consumption of banned agents.
This type of study suffers from the fact that  cause-and-effect
between HAI rates and changes in  antibiotic consumption are
notoriously difficult to prove [1].  Antimicrobial policy changes are
confounded by infection control practices on the wards, including
urinary and vascular catheter use [16,17].  In addition, there was
occasional use of related drugs such as moxifloxacin, levofloxacin
and cefuroxime, albeit at a  low level, which could have influ-
enced the effect of the policy. Meropenem consumption decreased
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throughout the study and could have had an impact on C.  difficile
rates, although there was no statistical correlation. We  believe that
this was because overall use of meropenem was low and, further-
more, it was generally only used for patients in intensive care.
Consumption of empirical amoxicillin and gentamicin escalated
throughout the study and could also have confounded the overall
effect. Given the surge in  gentamicin prescribing, we were forced
to monitor the management of dosage and levels, with auditing
of incidents regarding gentamicin. After initial turbulence, gen-
tamicin is now generally well managed, although resistance is
increasing among hospital isolates (data not included). Amoxicillin
resistance also increased among hospital E. coli isolates, although
this has only recently been detected. Ecological studies are limited
compared with individual-level analysis because is  not possible
to evaluate time as an important exposure variable related to
the emergence of resistance. The ecological ‘bias’ or  analysis of
aggregated data may  be compromised by the failure of level-effect
estimates to reflect the biological effect at the individual patient
level [18].
Whilst low rates of C.  difficile have been maintained to date,
it is possible that continued restrictions have influenced MRSA
and ESBL-producing coliform acquisition longer term, subject to
the  confounders already described. Three years after initiating the
antibiotic policy, the 2011 rate of hospital-acquired C. difficile was
0.259 cases/1000 pt-bds, for MRSA it was 0.409 cases/1000 pt-bds
and for ESBL-producing coliforms it was 0.809 cases/1000 pt-bds.
These rates are among the lowest achieved since the study began
and reflect observed lower rates of surgical site infection.
Retrospective search of the database for carbapenem resistance
among hospital-acquired ESBL-producing coliforms using appro-
priate clinical definitions identified five cases in  2008, one in  2009,
three in 2010, one in  2011 and none so far during 2012. These num-
bers are too small to draw any conclusions, but it is possible that the
restrictive policy has had some impact on extreme drug resistance
in this hospital. Three of the cases in 2008 were fatal [19]. Whilst
there have not been any specific interventions to control ESBL-
producing coliforms during the last 4 years, universal screening
for MRSA began in 2010 and continued throughout 2011. This
may  have contributed towards reduced hospital-acquired MRSA
in 2011, since there was only an insignificant reduction in MRSA
acquisition from 2007 to 2009 [5].
In conclusion, banning ceftriaxone and ciprofloxacin from first-
line  prescribing resulted in a  rapid reduction in  hospital-acquired
C. difficile, with smaller reductions in  ESBL-producing coliforms
and MRSA over an initial 2-year period. Quinolone consump-
tion appears to be driving ESBL-producing coliform acquisition in
this hospital. Continued restrictions on antibiotic prescribing have
helped maintain low rates of C.  difficile to date. Infection control
interventions aside, it is  possible that the policy has also impacted
upon ESBL-producing coliform and MRSA acquisition long term.
Antimicrobial stewardship is fundamental for controlling HAIs and
we should strive to reduce antibiotic use at all costs [20].
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